Clinical trials: Lymphoproliferative Malignancies
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.
- Conditions
- Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00038025
- Testing
- Deoxycoformycin (DCF)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Acute Lymphoblastic Leukemia
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
- Trial name
- NCT06559189
- Testing
- CD19x22 CAR T
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
Lymphocytic Leukemia
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: Personalized NeoAntigen Vaccine Poly-ICLC…
- Trial name
- NCT03219450
- Testing
- NeoVax, Cyclophosphamide, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Trauma Chest, Pediatric ALL
Point-of-Care Ultrasound for Pediatric Thoracic Trauma: A Multi-Institutional Trial
The objective of the proposed study is to investigate the diagnostic accuracy of ED POCUS in pediatric traumatic thoracic injuries including traumatic pneumothorax, hemothorax, lung contusion, rib fractures, and pulmonary edema…
- Trial name
- NCT05025150
- Where
- United States
- Volunteers
- 1,020 people
- Sponsor
- Sutter Health
Brain and Central Nervous System Tumors, Lymphoma
Melphalan With BBBD in Treating Patients With Brain Malignancies
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Trial name
- NCT00253721
- Testing
- Melphalan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- OHSU Knight Cancer Institute
Neoplasm
Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts
Most bone marrow transplantations for malignant and non-malignant disease include whole body irradiation. Techniques for administering that treatment, including patient positioning, lung and soft tissue compensation, dose rate…
- Trial name
- NCT00026858
- Testing
- collaboration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
- Trial name
- NCT00576758
- Testing
- obinutuzumab (RO5072759), rituximab
- Where
- 71 sites in United States, Argentina and 15 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4…
- Trial name
- NCT05028348
- Testing
- Selinexor, Elotuzumab, Pomalidomide
- Where
- 20 sites in France, Germany and 2 more
- Volunteers
- 117 people
- Sponsor
- European Myeloma Network B.V.
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma).
- Trial name
- NCT04288726
- Testing
- CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL
It is a treatment that activates and strengthens the immune system against cancer. Recently, T cell receptors have been genetically rearranged by adaptive T cell therapies, which are promising in the fight against cancer, and are…
- Trial name
- ISIKOK-19 (NCT04206943)
- Testing
- Car-T Cell Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Acibadem University
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
SARS-CoV-2 Donor-Recipient Immunity Transfer
This study investigates whether donors with previous exposure to COVID-19 can pass their immunity by hematopoietic (blood) stem cell transplant (HCT) donation to patients that have not been exposed.
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT04666025
- Testing
- Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard…
- Trial name
- NCT05016778
- Testing
- GPRC5D-CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
T-cell Lymphomas, T-cell Leukemia
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
This is a Phase II clinical trial aimed at treating a subgroup of patients with cutaneous T-cell lymphoma. The drug consists of a toxin, called diphtheria toxin, which is attached to an antibody that can specifically target…
- Conditions
- T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungoides
- Trial name
- NCT00611208
- Testing
- A-dmDT390-bisFv(UCHT1)
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Virogen Biotechnology Inc.
Multiple Myeloma
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
This is an open-label, multicenter clinical trial designed to evaluate the safety and potential efficacy of venetoclax and ABBV-838 combination therapy with dexamethasone in participants with relapsed or refractory multiple…
- Trial name
- NCT02951117
- Testing
- Venetoclax, ABBV-838, Dexamethasone
- Where
- 3 sites in Australia
- Sponsor
- AbbVie
Lymphoma
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004889
- Testing
- rituximab
- Where
- 8 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment…
- Trial name
- NCT02843074
- Testing
- elotuzumab, Lenalidomide, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 53 people
- Sponsor
- SCRI Development Innovations, LLC
Diffuse Large B-Cell Lymphoma, Drug Toxicity
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subset of non-Hodgkin's lymphoma (NHL). Central nervous system (CNS) involvement in patients with NHL is a serious complication.
- Trial name
- NCT05022797
- Testing
- Glucarpidase 1000 UNT [Voraxaze]
- Where
- 2 sites in Spain
- Volunteers
- 3 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)
ABO and Rh Blood Group Frequencies in Acute Leukemia Patients
This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia.
- Trial name
- NCT07108010
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Assiut University
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.
- Trial name
- V+DA-EPOCH-R (NCT03036904)
- Testing
- Venetoclax, Rituximab, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Weill Medical College of Cornell University